Share Price and Basic Stock Data
Last Updated: January 2, 2026, 6:47 pm
| PEG Ratio | -13.55 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Zydus Wellness Ltd operates in the food processing sector, focusing on bakery, dairy, fruits, and other products. As of the latest price of ₹469, the company has a market capitalization of ₹14,875 Cr. Over the past fiscal years, Zydus Wellness has shown a steady increase in revenue, with sales rising from ₹2,009 Cr in March 2022 to ₹2,255 Cr in March 2023, and further to ₹2,328 Cr in March 2024. The trailing twelve months (TTM) revenue stood at ₹2,886 Cr, indicating robust growth momentum. Quarterly sales have exhibited variability, with Q4 FY 2025 recording sales of ₹913 Cr, compared to ₹403 Cr in Q2 FY 2024. This illustrates the company’s ability to capitalize on seasonal demand and product launches. However, sales of ₹440 Cr in Q2 FY 2025 reflect a decline compared to the preceding quarter, suggesting potential volatility in revenue streams. Zydus Wellness’s ability to sustain growth in a competitive environment will be critical for its long-term success.
Profitability and Efficiency Metrics
Zydus Wellness reported a net profit of ₹253 Cr, translating to a net profit margin of 12.80% for March 2025. The company’s operating profit margin (OPM) stood at 14.51% for the same period, reflecting operational efficiencies. However, OPM has shown a declining trend, from 17% in June 2023 to 14.51% in March 2025. The interest coverage ratio (ICR) is notably strong at 32.77x, indicating that the company comfortably meets its interest obligations. Return on equity (ROE) is 6.11%, while return on capital employed (ROCE) is 6.40%, both of which are relatively low compared to industry benchmarks. The cash conversion cycle stands at 75 days, suggesting effective management of working capital. However, rising expenses, which increased from ₹1,664 Cr in March 2022 to ₹2,329 Cr in March 2025, could pressure future profitability. The ability to manage costs while maintaining revenue growth will be pivotal for sustaining margins.
Balance Sheet Strength and Financial Ratios
Zydus Wellness’s balance sheet demonstrates a prudent financial structure, with total borrowings of ₹3,042 Cr against reserves of ₹5,642 Cr as of March 2025. The debt-to-equity ratio is low at 0.03, indicating minimal reliance on debt financing. The company reported a book value per share of ₹891.76, reflecting solid asset backing. Current and quick ratios are 1.48 and 0.78, respectively, suggesting good short-term liquidity, though the quick ratio indicates potential challenges in meeting immediate liabilities without liquidating inventory. The enterprise value (EV) stands at ₹10,742.16 Cr, with an EV/EBITDA of 27.31x, which may reflect investor expectations of future growth. However, the price-to-book (P/BV) ratio is 1.87x, indicating that the stock is valued higher than its book value, which could imply overvaluation concerns in a market correction. Overall, the balance sheet appears strong, but the high valuation metrics warrant careful consideration.
Shareholding Pattern and Investor Confidence
As of March 2025, Zydus Wellness has a diverse shareholding structure, with promoters holding 69.64% of the shares, which signals strong control and commitment to the company. Foreign Institutional Investors (FIIs) own 3.29%, while Domestic Institutional Investors (DIIs) hold 19.76%. Public shareholding stands at 7.30%, indicating a relatively low retail investor base. The number of shareholders has consistently increased from 68,969 in December 2022 to 77,188 by September 2025, reflecting growing interest in the company. However, the gradual decline in DII holdings from 23.35% in December 2022 to 19.76% in March 2025 could be a concern, suggesting potential shifts in institutional sentiment. The stable promoter holding combined with increasing shareholder numbers may instill confidence among investors, but the decline in institutional investments could indicate caution among larger investors.
Outlook, Risks, and Final Insight
Looking ahead, Zydus Wellness faces both opportunities and challenges. The company’s strong revenue growth, evidenced by a TTM figure of ₹2,886 Cr, positions it well within the competitive food processing market. However, risks include rising operational costs, as demonstrated by increasing expenses and declining OPM, which may pressure future profitability. Furthermore, the company’s relatively low ROE and ROCE raise concerns about capital efficiency. The ongoing changes in the shareholding pattern, particularly the decrease in DII holdings, could signal hesitance from institutional investors. Zydus Wellness must focus on enhancing operational efficiencies and managing costs effectively to sustain growth. If it successfully navigates these risks, the company may leverage its market position for continued expansion. However, failure to address these challenges could hinder its growth trajectory in a fluctuating economic environment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mishtann Foods Ltd | 538 Cr. | 4.99 | 7.79/4.28 | 1.61 | 10.9 | 0.00 % | 42.2 % | 44.1 % | 1.00 |
| Mrs Bectors Food Specialities Ltd | 7,509 Cr. | 244 | 355/224 | 55.1 | 39.6 | 0.49 % | 18.1 % | 15.6 % | 2.00 |
| Nakoda Group of Industries Ltd | 52.5 Cr. | 30.0 | 44.2/22.2 | 18.8 | 0.00 % | 8.11 % | 15.4 % | 10.0 | |
| HMA Agro Industries Ltd | 1,491 Cr. | 29.5 | 41.6/27.5 | 12.0 | 17.3 | 1.02 % | 11.8 % | 11.5 % | 1.00 |
| Himalaya Food International Ltd | 82.4 Cr. | 9.72 | 18.6/8.95 | 14.3 | 21.8 | 0.00 % | 2.29 % | 2.79 % | 10.0 |
| Industry Average | 21,762.67 Cr | 677.36 | 133.91 | 91.71 | 0.25% | 16.37% | 17.51% | 5.78 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 429 | 416 | 713 | 702 | 440 | 403 | 783 | 841 | 493 | 462 | 913 | 861 | 650 |
| Expenses | 413 | 388 | 568 | 586 | 423 | 390 | 620 | 686 | 473 | 447 | 723 | 705 | 628 |
| Operating Profit | 16 | 28 | 145 | 116 | 17 | 13 | 162 | 155 | 20 | 15 | 190 | 156 | 23 |
| OPM % | 4% | 7% | 20% | 17% | 4% | 3% | 21% | 18% | 4% | 3% | 21% | 18% | 4% |
| Other Income | 1 | 1 | -6 | -12 | 4 | 3 | 4 | 5 | 10 | 4 | 1 | 3 | -33 |
| Interest | 3 | 4 | 5 | 5 | 6 | 6 | 6 | 4 | 1 | 3 | 4 | 2 | 16 |
| Depreciation | 6 | 6 | 7 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 13 | 11 | 25 |
| Profit before tax | 8 | 19 | 126 | 93 | 9 | 4 | 154 | 152 | 24 | 10 | 173 | 145 | -51 |
| Tax % | -4% | -1% | -15% | -18% | 31% | 92% | 3% | 3% | 12% | 37% | 1% | 12% | 4% |
| Net Profit | 8 | 20 | 145 | 110 | 6 | 0 | 150 | 148 | 21 | 6 | 172 | 128 | -53 |
| EPS in Rs | 0.27 | 0.62 | 4.57 | 3.47 | 0.19 | 0.01 | 4.72 | 4.64 | 0.66 | 0.20 | 5.40 | 4.02 | -1.66 |
Last Updated: January 2, 2026, 4:41 pm
Below is a detailed analysis of the quarterly data for Zydus Wellness Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 650.00 Cr.. The value appears to be declining and may need further review. It has decreased from 861.00 Cr. (Jun 2025) to 650.00 Cr., marking a decrease of 211.00 Cr..
- For Expenses, as of Sep 2025, the value is 628.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 705.00 Cr. (Jun 2025) to 628.00 Cr., marking a decrease of 77.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 23.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Jun 2025) to 23.00 Cr., marking a decrease of 133.00 Cr..
- For OPM %, as of Sep 2025, the value is 4.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Jun 2025) to 4.00%, marking a decrease of 14.00%.
- For Other Income, as of Sep 2025, the value is -33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Jun 2025) to -33.00 Cr., marking a decrease of 36.00 Cr..
- For Interest, as of Sep 2025, the value is 16.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Jun 2025) to 16.00 Cr., marking an increase of 14.00 Cr..
- For Depreciation, as of Sep 2025, the value is 25.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.00 Cr. (Jun 2025) to 25.00 Cr., marking an increase of 14.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -51.00 Cr.. The value appears to be declining and may need further review. It has decreased from 145.00 Cr. (Jun 2025) to -51.00 Cr., marking a decrease of 196.00 Cr..
- For Tax %, as of Sep 2025, the value is 4.00%. The value appears to be improving (decreasing) as expected. It has decreased from 12.00% (Jun 2025) to 4.00%, marking a decrease of 8.00%.
- For Net Profit, as of Sep 2025, the value is -53.00 Cr.. The value appears to be declining and may need further review. It has decreased from 128.00 Cr. (Jun 2025) to -53.00 Cr., marking a decrease of 181.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is -1.66. The value appears to be declining and may need further review. It has decreased from 4.02 (Jun 2025) to -1.66, marking a decrease of 5.68.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:44 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 404 | 431 | 397 | 431 | 513 | 843 | 1,767 | 1,867 | 2,009 | 2,255 | 2,328 | 2,709 | 2,886 |
| Expenses | 319 | 331 | 305 | 331 | 387 | 658 | 1,446 | 1,522 | 1,664 | 1,918 | 2,020 | 2,329 | 2,503 |
| Operating Profit | 85 | 100 | 91 | 99 | 125 | 185 | 321 | 344 | 345 | 337 | 308 | 380 | 383 |
| OPM % | 21% | 23% | 23% | 23% | 24% | 22% | 18% | 18% | 17% | 15% | 13% | 14% | 13% |
| Other Income | 19 | 28 | 32 | 32 | 35 | 28 | -33 | -123 | 10 | -5 | -0 | 19 | -25 |
| Interest | 0 | 0 | 0 | 1 | 2 | 30 | 140 | 84 | 26 | 16 | 24 | 12 | 26 |
| Depreciation | 0 | 8 | 7 | 7 | 9 | 13 | 26 | 25 | 24 | 25 | 24 | 28 | 54 |
| Profit before tax | 104 | 120 | 117 | 124 | 150 | 171 | 121 | 112 | 306 | 291 | 260 | 359 | 278 |
| Tax % | 5% | 7% | 10% | 10% | 9% | -0% | -17% | -6% | -1% | -7% | -3% | 3% | |
| Net Profit | 98 | 111 | 105 | 111 | 137 | 171 | 142 | 119 | 309 | 310 | 267 | 347 | 253 |
| EPS in Rs | 4.94 | 5.58 | 5.28 | 5.58 | 6.85 | 5.87 | 4.92 | 3.73 | 9.71 | 9.75 | 8.39 | 10.90 | 7.96 |
| Dividend Payout % | 24% | 22% | 25% | 23% | 23% | 17% | 20% | 27% | 10% | 10% | 12% | 11% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 13.27% | -5.41% | 5.71% | 23.42% | 24.82% | -16.96% | -16.20% | 159.66% | 0.32% | -13.87% | 29.96% |
| Change in YoY Net Profit Growth (%) | 0.00% | -18.67% | 11.12% | 17.71% | 1.39% | -41.78% | 0.76% | 175.86% | -159.34% | -14.19% | 43.83% |
Zydus Wellness Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 9% |
| 3 Years: | 10% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 13% |
| 3 Years: | 2% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | 14% |
| 1 Year: | 7% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 6% |
| Last Year: | 6% |
Last Updated: September 4, 2025, 9:45 pm
Balance Sheet
Last Updated: December 4, 2025, 12:52 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 39 | 39 | 39 | 39 | 39 | 58 | 58 | 64 | 64 | 64 | 64 | 64 | 64 |
| Reserves | 286 | 367 | 439 | 518 | 652 | 3,329 | 3,403 | 4,504 | 4,780 | 5,059 | 5,294 | 5,608 | 5,642 |
| Borrowings | 0 | 0 | 0 | 25 | 25 | 1,569 | 1,519 | 550 | 387 | 297 | 329 | 188 | 3,042 |
| Other Liabilities | 99 | 102 | 89 | 100 | 112 | 503 | 610 | 548 | 461 | 413 | 462 | 582 | 1,134 |
| Total Liabilities | 425 | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,442 | 9,882 |
| Fixed Assets | 95 | 84 | 82 | 103 | 104 | 4,567 | 4,674 | 4,667 | 4,710 | 4,732 | 4,708 | 5,125 | 8,446 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 10 | 4 | 4 | 12 | 13 | 10 | 15 | 13 |
| Investments | 5 | 0 | 94 | 30 | 148 | 46 | 110 | 0 | 27 | 70 | 78 | 36 | 28 |
| Other Assets | 324 | 423 | 391 | 550 | 577 | 835 | 802 | 995 | 943 | 1,018 | 1,354 | 1,266 | 1,394 |
| Total Assets | 425 | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,442 | 9,882 |
Below is a detailed analysis of the balance sheet data for Zydus Wellness Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 64.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 64.00 Cr..
- For Reserves, as of Sep 2025, the value is 5,642.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,608.00 Cr. (Mar 2025) to 5,642.00 Cr., marking an increase of 34.00 Cr..
- For Borrowings, as of Sep 2025, the value is 3,042.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 188.00 Cr. (Mar 2025) to 3,042.00 Cr., marking an increase of 2,854.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,134.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 582.00 Cr. (Mar 2025) to 1,134.00 Cr., marking an increase of 552.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 9,882.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,442.00 Cr. (Mar 2025) to 9,882.00 Cr., marking an increase of 3,440.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 8,446.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,125.00 Cr. (Mar 2025) to 8,446.00 Cr., marking an increase of 3,321.00 Cr..
- For CWIP, as of Sep 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 15.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 36.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 8.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,394.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,266.00 Cr. (Mar 2025) to 1,394.00 Cr., marking an increase of 128.00 Cr..
- For Total Assets, as of Sep 2025, the value is 9,882.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,442.00 Cr. (Mar 2025) to 9,882.00 Cr., marking an increase of 3,440.00 Cr..
Notably, the Reserves (5,642.00 Cr.) exceed the Borrowings (3,042.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 85.00 | 100.00 | 91.00 | 74.00 | 100.00 | 184.00 | 320.00 | -206.00 | -42.00 | 40.00 | -21.00 | 192.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 2 | 1 | 3 | 3 | 6 | 42 | 24 | 18 | 26 | 34 | 44 | 49 |
| Inventory Days | 108 | 76 | 73 | 127 | 113 | 393 | 168 | 158 | 135 | 146 | 150 | 148 |
| Days Payable | 191 | 146 | 191 | 264 | 254 | 662 | 289 | 189 | 136 | 100 | 116 | 122 |
| Cash Conversion Cycle | -82 | -69 | -116 | -134 | -135 | -227 | -97 | -13 | 25 | 80 | 78 | 75 |
| Working Capital Days | -48 | -37 | -38 | -57 | -26 | -26 | -7 | -35 | -27 | 17 | 20 | 34 |
| ROCE % | 35% | 32% | 26% | 23% | 22% | 7% | 6% | 6% | 6% | 6% | 5% | 6% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Parag Parikh Flexi Cap Fund | 22,000,000 | 0.73 | 946.99 | N/A | N/A | N/A |
| Nippon India Small Cap Fund | 16,848,030 | 1.06 | 725.22 | 2,221,106 | 2025-12-08 07:42:13 | 658.54% |
| Quant Small Cap Fund | 9,033,845 | 1.29 | 388.86 | N/A | N/A | N/A |
| Nippon India Consumption Fund | 1,358,672 | 2.1 | 58.48 | 1,403,000 | 2025-12-15 00:28:01 | -3.16% |
| Quant Multi Cap Fund | 1,250,000 | 0.61 | 53.81 | N/A | N/A | N/A |
| Parag Parikh ELSS Tax Saver Fund | 1,135,555 | 0.83 | 48.88 | N/A | N/A | N/A |
| Quant ESG Integration Strategy Fund | 426,074 | 6.72 | 18.34 | 432,771 | 2025-12-15 00:28:01 | -1.55% |
| Baroda BNP Paribas India Consumption Fund | 300,000 | 0.83 | 12.91 | N/A | N/A | N/A |
| Union Value Fund | 82,500 | 0.96 | 3.55 | N/A | N/A | N/A |
| Taurus ELSS Tax Saver Fund | 54,975 | 3.05 | 2.37 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 37.00 | 41.94 | 48.78 | 48.54 | 19.55 |
| Diluted EPS (Rs.) | 37.00 | 41.94 | 48.78 | 48.54 | 19.55 |
| Cash EPS (Rs.) | 59.01 | 45.71 | 52.71 | 52.25 | 22.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 891.76 | 842.37 | 805.07 | 761.28 | 717.87 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 891.76 | 842.37 | 805.07 | 761.28 | 717.87 |
| Revenue From Operations / Share (Rs.) | 425.93 | 366.01 | 354.36 | 315.75 | 293.36 |
| PBDIT / Share (Rs.) | 61.84 | 50.64 | 53.75 | 55.81 | 55.52 |
| PBIT / Share (Rs.) | 57.37 | 46.90 | 49.82 | 52.10 | 51.57 |
| PBT / Share (Rs.) | 56.41 | 40.90 | 45.71 | 48.09 | 17.63 |
| Net Profit / Share (Rs.) | 54.54 | 41.97 | 48.78 | 48.54 | 18.66 |
| NP After MI And SOA / Share (Rs.) | 54.54 | 41.97 | 48.78 | 48.54 | 18.66 |
| PBDIT Margin (%) | 14.51 | 13.83 | 15.16 | 17.67 | 18.92 |
| PBIT Margin (%) | 13.47 | 12.81 | 14.05 | 16.50 | 17.57 |
| PBT Margin (%) | 13.24 | 11.17 | 12.89 | 15.23 | 6.01 |
| Net Profit Margin (%) | 12.80 | 11.46 | 13.76 | 15.37 | 6.36 |
| NP After MI And SOA Margin (%) | 12.80 | 11.46 | 13.76 | 15.37 | 6.36 |
| Return on Networth / Equity (%) | 6.11 | 4.98 | 6.05 | 6.37 | 2.59 |
| Return on Capital Employeed (%) | 6.40 | 5.54 | 6.16 | 6.73 | 6.70 |
| Return On Assets (%) | 5.38 | 4.34 | 5.32 | 5.42 | 2.09 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.06 |
| Total Debt / Equity (X) | 0.03 | 0.06 | 0.05 | 0.07 | 0.12 |
| Asset Turnover Ratio (%) | 0.43 | 0.38 | 0.05 | 0.04 | 0.02 |
| Current Ratio (X) | 1.48 | 1.62 | 1.31 | 1.06 | 1.10 |
| Quick Ratio (X) | 0.78 | 1.02 | 0.65 | 0.58 | 0.62 |
| Inventory Turnover Ratio (X) | 5.50 | 2.24 | 0.89 | 0.78 | 0.54 |
| Dividend Payout Ratio (NP) (%) | 9.16 | 11.91 | 10.25 | 10.30 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 8.47 | 10.93 | 9.48 | 9.57 | 0.00 |
| Earning Retention Ratio (%) | 90.84 | 88.09 | 89.75 | 89.70 | 0.00 |
| Cash Earning Retention Ratio (%) | 91.53 | 89.07 | 90.52 | 90.43 | 0.00 |
| Interest Coverage Ratio (X) | 32.77 | 13.42 | 21.27 | 13.92 | 4.22 |
| Interest Coverage Ratio (Post Tax) (X) | 29.42 | 12.71 | 20.93 | 13.11 | 3.99 |
| Enterprise Value (Cr.) | 10742.16 | 9439.42 | 10116.33 | 9760.97 | 12849.96 |
| EV / Net Operating Revenue (X) | 3.97 | 4.05 | 4.49 | 4.86 | 6.88 |
| EV / EBITDA (X) | 27.31 | 29.31 | 29.58 | 27.48 | 36.37 |
| MarketCap / Net Operating Revenue (X) | 3.92 | 4.02 | 4.37 | 4.75 | 6.72 |
| Retention Ratios (%) | 90.83 | 88.08 | 89.74 | 89.69 | 0.00 |
| Price / BV (X) | 1.87 | 1.75 | 1.93 | 1.97 | 2.75 |
| Price / Net Operating Revenue (X) | 3.92 | 4.02 | 4.37 | 4.75 | 6.72 |
| EarningsYield | 0.03 | 0.02 | 0.03 | 0.03 | 0.01 |
After reviewing the key financial ratios for Zydus Wellness Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 37.00. This value is within the healthy range. It has decreased from 41.94 (Mar 24) to 37.00, marking a decrease of 4.94.
- For Diluted EPS (Rs.), as of Mar 25, the value is 37.00. This value is within the healthy range. It has decreased from 41.94 (Mar 24) to 37.00, marking a decrease of 4.94.
- For Cash EPS (Rs.), as of Mar 25, the value is 59.01. This value is within the healthy range. It has increased from 45.71 (Mar 24) to 59.01, marking an increase of 13.30.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 891.76. It has increased from 842.37 (Mar 24) to 891.76, marking an increase of 49.39.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 891.76. It has increased from 842.37 (Mar 24) to 891.76, marking an increase of 49.39.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 425.93. It has increased from 366.01 (Mar 24) to 425.93, marking an increase of 59.92.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 61.84. This value is within the healthy range. It has increased from 50.64 (Mar 24) to 61.84, marking an increase of 11.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is 57.37. This value is within the healthy range. It has increased from 46.90 (Mar 24) to 57.37, marking an increase of 10.47.
- For PBT / Share (Rs.), as of Mar 25, the value is 56.41. This value is within the healthy range. It has increased from 40.90 (Mar 24) to 56.41, marking an increase of 15.51.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 54.54. This value is within the healthy range. It has increased from 41.97 (Mar 24) to 54.54, marking an increase of 12.57.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 54.54. This value is within the healthy range. It has increased from 41.97 (Mar 24) to 54.54, marking an increase of 12.57.
- For PBDIT Margin (%), as of Mar 25, the value is 14.51. This value is within the healthy range. It has increased from 13.83 (Mar 24) to 14.51, marking an increase of 0.68.
- For PBIT Margin (%), as of Mar 25, the value is 13.47. This value is within the healthy range. It has increased from 12.81 (Mar 24) to 13.47, marking an increase of 0.66.
- For PBT Margin (%), as of Mar 25, the value is 13.24. This value is within the healthy range. It has increased from 11.17 (Mar 24) to 13.24, marking an increase of 2.07.
- For Net Profit Margin (%), as of Mar 25, the value is 12.80. This value exceeds the healthy maximum of 10. It has increased from 11.46 (Mar 24) to 12.80, marking an increase of 1.34.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.80. This value is within the healthy range. It has increased from 11.46 (Mar 24) to 12.80, marking an increase of 1.34.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.11. This value is below the healthy minimum of 15. It has increased from 4.98 (Mar 24) to 6.11, marking an increase of 1.13.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.40. This value is below the healthy minimum of 10. It has increased from 5.54 (Mar 24) to 6.40, marking an increase of 0.86.
- For Return On Assets (%), as of Mar 25, the value is 5.38. This value is within the healthy range. It has increased from 4.34 (Mar 24) to 5.38, marking an increase of 1.04.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has decreased from 0.06 (Mar 24) to 0.03, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.43. It has increased from 0.38 (Mar 24) to 0.43, marking an increase of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.48. This value is below the healthy minimum of 1.5. It has decreased from 1.62 (Mar 24) to 1.48, marking a decrease of 0.14.
- For Quick Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 24) to 0.78, marking a decrease of 0.24.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.50. This value is within the healthy range. It has increased from 2.24 (Mar 24) to 5.50, marking an increase of 3.26.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.16. This value is below the healthy minimum of 20. It has decreased from 11.91 (Mar 24) to 9.16, marking a decrease of 2.75.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.47. This value is below the healthy minimum of 20. It has decreased from 10.93 (Mar 24) to 8.47, marking a decrease of 2.46.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.84. This value exceeds the healthy maximum of 70. It has increased from 88.09 (Mar 24) to 90.84, marking an increase of 2.75.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.53. This value exceeds the healthy maximum of 70. It has increased from 89.07 (Mar 24) to 91.53, marking an increase of 2.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 32.77. This value is within the healthy range. It has increased from 13.42 (Mar 24) to 32.77, marking an increase of 19.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 29.42. This value is within the healthy range. It has increased from 12.71 (Mar 24) to 29.42, marking an increase of 16.71.
- For Enterprise Value (Cr.), as of Mar 25, the value is 10,742.16. It has increased from 9,439.42 (Mar 24) to 10,742.16, marking an increase of 1,302.74.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.97. This value exceeds the healthy maximum of 3. It has decreased from 4.05 (Mar 24) to 3.97, marking a decrease of 0.08.
- For EV / EBITDA (X), as of Mar 25, the value is 27.31. This value exceeds the healthy maximum of 15. It has decreased from 29.31 (Mar 24) to 27.31, marking a decrease of 2.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.92. This value exceeds the healthy maximum of 3. It has decreased from 4.02 (Mar 24) to 3.92, marking a decrease of 0.10.
- For Retention Ratios (%), as of Mar 25, the value is 90.83. This value exceeds the healthy maximum of 70. It has increased from 88.08 (Mar 24) to 90.83, marking an increase of 2.75.
- For Price / BV (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has increased from 1.75 (Mar 24) to 1.87, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.92. This value exceeds the healthy maximum of 3. It has decreased from 4.02 (Mar 24) to 3.92, marking a decrease of 0.10.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Zydus Wellness Ltd:
- Net Profit Margin: 12.8%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.4% (Industry Average ROCE: 16.37%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.11% (Industry Average ROE: 17.51%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 29.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.78
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 52.8 (Industry average Stock P/E: 133.91)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.8%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Food Processing - Bakery/Dairy/Fruits/Others | Zydus Corporate Park, Ahmedabad Gujarat 382481 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Sharvil P Patel | Chairman |
| Mr. Tarun G Arora | WholeTime Director & CEO |
| Mr. Ganesh N Nayak | Non Executive Director |
| Mr. Kulin S Lalbhai | Independent Director |
| Mr. Akhil A Monappa | Independent Director |
| Mr. Srivishnu Raju Nandyala | Independent Director |
| Ms. Dharmishtaben N Raval | Independent Woman Director |
FAQ
What is the intrinsic value of Zydus Wellness Ltd?
Zydus Wellness Ltd's intrinsic value (as of 02 January 2026) is ₹456.31 which is 2.71% lower the current market price of ₹469.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹14,875 Cr. market cap, FY2025-2026 high/low of ₹531/299, reserves of ₹5,642 Cr, and liabilities of ₹9,882 Cr.
What is the Market Cap of Zydus Wellness Ltd?
The Market Cap of Zydus Wellness Ltd is 14,875 Cr..
What is the current Stock Price of Zydus Wellness Ltd as on 02 January 2026?
The current stock price of Zydus Wellness Ltd as on 02 January 2026 is ₹469.
What is the High / Low of Zydus Wellness Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Zydus Wellness Ltd stocks is ₹531/299.
What is the Stock P/E of Zydus Wellness Ltd?
The Stock P/E of Zydus Wellness Ltd is 52.8.
What is the Book Value of Zydus Wellness Ltd?
The Book Value of Zydus Wellness Ltd is 179.
What is the Dividend Yield of Zydus Wellness Ltd?
The Dividend Yield of Zydus Wellness Ltd is 0.25 %.
What is the ROCE of Zydus Wellness Ltd?
The ROCE of Zydus Wellness Ltd is 6.16 %.
What is the ROE of Zydus Wellness Ltd?
The ROE of Zydus Wellness Ltd is 6.02 %.
What is the Face Value of Zydus Wellness Ltd?
The Face Value of Zydus Wellness Ltd is 2.00.